Kevin B. Jones, MD

Languages spoken: English, Spanish
MyChart

Clinical Locations

  • Kevin B. Jones, MD

    Leader, Huntsman Cancer Institute Sarcoma Disease Center

    Division Chief, Sarcoma, Department of Orthopaedics

    Professor, Department of Orthopaedics and

    Adjunct Professor of Oncological Sciences

    As an orthopaedic surgeon specialized in the care of pediatric and adult patients with sarcoma, I see first-hand the limitations and frank failures of the currently available treatment options. Not only do we fail to cure far too many young patients with sarcomas, but the long-term effects of our treatments create other major challenges to the health of the survivors in the long term.

    With protected time for basic investigation, I dedicate my entire laboratory to the study of pediatric and young adult fusion oncogene-associated sarcomas. In efforts always angling toward improved targeted therapies, we use mouse genetic models of sarcomagenesis to dissect pathways of importance to initiation and progression of tumors. This work utilizes conditional activation of translocation-associated fusion oncogenes as well as manipulation of additional modifying genes directed toward improved understanding of the conditions that promote or inhibit sarcomagenesis. This work has led to generous experience with comparative genomics and epigenomics.

    The simple genetic changes that drive translocation-associated sarcomas make a strong argument for cancer being defined as a transcriptional state for cells, rather than a state of accumulated mutations or genetic losses and gains. The study of the epigenetic determinants of this transcriptional state in cells that harbor very few genetic code alterations has already revealed important knowledge that pertains to more complex genome cancer types as well as to transcriptional biology more generally.

    I also believe firmly in the synergy possible in collaborative team science. Such efforts are required for progress toward improved treatments for rare malignancies that can never be studied with optimal efficacy in a silo. With such collaborative work as direct goal, I have participated in and assembled teams to work on pediatric sarcomas both within my institution and internationally.

    Board Certification and Academic Information

    Academic Departments Orthopaedics - Primary
    Oncological Sciences - Adjunct

    Patient Rating

    4.8/5

    The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.

    Responses are measured on a scale of 1 to 5 with 5 being the best score.

    Learn more about our survey

    Patient Comments

    Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    November 12, 2022

    Blessings on Dr. JONES & his staff!

    November 03, 2022

    I waited 45 minutes

    October 06, 2022

    Dr. Jones is really concerned about his patients

    See More Patient Comments

  • Kevin B. Jones, MD

    Leader, Huntsman Cancer Institute Sarcoma Disease Center

    Division Chief, Sarcoma, Department of Orthopaedics

    Professor, Department of Orthopaedics and

    Adjunct Professor of Oncological Sciences

    As an orthopaedic surgeon specialized in the care of pediatric and adult patients with sarcoma, I see first-hand the limitations and frank failures of the currently available treatment options. Not only do we fail to cure far too many young patients with sarcomas, but the long-term effects of our treatments create other major challenges to the health of the survivors in the long term.

    With protected time for basic investigation, I dedicate my entire laboratory to the study of pediatric and young adult fusion oncogene-associated sarcomas. In efforts always angling toward improved targeted therapies, we use mouse genetic models of sarcomagenesis to dissect pathways of importance to initiation and progression of tumors. This work utilizes conditional activation of translocation-associated fusion oncogenes as well as manipulation of additional modifying genes directed toward improved understanding of the conditions that promote or inhibit sarcomagenesis. This work has led to generous experience with comparative genomics and epigenomics.

    The simple genetic changes that drive translocation-associated sarcomas make a strong argument for cancer being defined as a transcriptional state for cells, rather than a state of accumulated mutations or genetic losses and gains. The study of the epigenetic determinants of this transcriptional state in cells that harbor very few genetic code alterations has already revealed important knowledge that pertains to more complex genome cancer types as well as to transcriptional biology more generally.

    I also believe firmly in the synergy possible in collaborative team science. Such efforts are required for progress toward improved treatments for rare malignancies that can never be studied with optimal efficacy in a silo. With such collaborative work as direct goal, I have participated in and assembled teams to work on pediatric sarcomas both within my institution and internationally.

    Board Certification and Academic Information

    Academic Departments Orthopaedics -Primary
    Oncological Sciences -Adjunct

    Research interests

    Education history

    Other Training Mentored Scientific Training-Mouse Genetic Modeling of Sarcoma - Mario Capecchi Laboratory, University of Utah
    Musculoskeletal Oncology - Mount Sinai Hospital Fellow
    Residency Orthopaedic Surgery - University of Iowa Hospitals and Clinics Resident
    Medicine - Johns Hopkins University M.D.
    Undergraduate English and American Literature and Language - Harvard University A.B.